viewAzurRx BioPharma Inc

AzurRx BioPharma reports positive results in its Phase 2a trial of pancreatitis drug

MS1819-SD was developed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis

The drug may also be able to be applied to the treatment of cystic fibrosis

AzurRx BioPharma Inc (NASDAQ:AZRX) announced a successful Phase 2a trial study of its pancreatitis drug.

MS1819-SD is designed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis, a disease characterized by inflammation of the pancreas.

READ: Trevena shares pop on successful completion of Phase 1 study of acute migraine treatment

Initial data from the study shows a “very strong safety and efficacy profile”, according to the company’s press statement.

The Brooklyn-based biopharma will look into applying the drug to the treatment of cystic fibrosis as well.

“Based on these data, we believe we have the basis for initiating a Phase IIb trial of MS1819 in cystic fibrosis patients in the fall of 2018,” said Chief Medical Officer James Pennington in a statement.

The biopharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. While MS1819 is its lead drug candidate, it is also conducting early-stage research into the prevention of hospital-acquired infections.

Shares jumped nearly 8% to US$3.16 in Friday morning trading.

Quick facts: AzurRx BioPharma Inc

Price: 0.97 USD

Market: NASDAQ
Market Cap: $26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Search Minerals hoping to use patented technology in...

Search Minerals Inc. (CVE: SMY) President and CEO Greg Andrews joined Steve Darling from Proactive in Vancouver to discuss the company that if focuses on the exploration and development of the Critical Rare Earth Element District in Southeastern Labrador, Canada.  Andrews talks about...

12 hours, 11 minutes ago

2 min read